和誉-B(02256.HK)：于ESMO Asia 2025公布口服PD-L1抑制剂ABSK043联合EGFR抑制剂伏美替尼治疗NSCLC的II期临床初步结果

Core Insights - The company, He Yu-B (02256.HK), announced preliminary results from its Phase II clinical study (ABSK043-202) of the oral small molecule PD-L1 inhibitor, ABSK043, in combination with the third-generation EGFR-TKI, Furmetinib, for the treatment of non-small cell lung cancer (NSCLC) [1] Group 1: Clinical Study Results - The combination therapy of ABSK043 and Furmetinib demonstrated good safety and tolerability [1] - Regulatory authorities have approved the expansion of the study to include first-line treatment for EGFR mutation-positive and PD-L1 positive NSCLC patients based on the favorable safety profile [1]